Tratamiento del cancer avanzado de colon
Coordinador: Dr Juan Manuel O’Connor - Certificacion 10 hs docentes CRAMA –Tiempo para cursar y rendir : 6 meses – Se cursa y se rinde on line – La actualizacion comienza cuando se inscribe. Recibira usuario y clave de acceso.
Programa
- Presentación
- Conflictos de interés
- Agenda
- Incidencia y mortalidad
- Algo de la historia del tratamiento del CRC
- Advanced CRC: Where are we and where are we going?
- The era after FIRE-3 and CALGB/SWOG 80405
- Clinical implications of biomarkers in CRC cancer
- Having a biomarker for a targeted therapy is associated with significantly better outcomes
- Number of targeted therapeutics is rising
- Oncology critical trial
- Terapeutic approaches
- High concordance between ras genotype in liquid biopsies and tissue samples in our study
- New anti-EGFR agents
- Therapeutic strategies to overcome overexpression of ligands
- MCLA-158: EFGR x Lgr5 Biclonics
- BI-specificity confers more potency not depending and LGR-5, even in RAS mut tumors
- BRAF gene
- What is the prognosis of non-V600E BRAF mutations
- From single targeting to multi-targeting: Increasing clinical benefit in MCRC
- FOLFOXIRI for 1st line metastatic BRAF V600E CRC
- Phase II trial design Volfi trial
- Folfoxri plus planitumumab
- Ensayos clínicos
- Combined BRAF, EGFR and MEK
- Optimization of immunotherapy in CRC
- Cuantos pacientes con CRC MSI logran respuesta obejtiva al tratamiento
- La respuesta antitumoral con el esquema combinado y resistencia primaria entre los estudios
- Tumor mutational load (TML) Distribution Across 14 gastrointestinal cancer types
- FIRE-4: Cetuximab Rechallenge
- Planned: FIRE-6 Avelumab study
- Conclusiones
- NICHE: Study in early stage colon cancer